Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma
出版年份 2014 全文链接
标题
Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma
作者
关键词
-
出版物
BLOOD
Volume 125, Issue 8, Pages 1236-1243
出版商
American Society of Hematology
发表日期
2014-12-23
DOI
10.1182/blood-2014-08-595801
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center
- (2013) A. Gibb et al. HAEMATOLOGICA
- Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma
- (2013) Sylvain Garciaz et al. HEMATOLOGICAL ONCOLOGY
- Seven-year follow-up of allogeneic transplant using BCNU, etoposide, cytarabine and melphalan chemotherapy in patients with Hodgkin lymphoma after autograft failure: importance of minimal residual disease
- (2013) Urszula Sobol et al. LEUKEMIA & LYMPHOMA
- Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant
- (2013) Sally Arai et al. LEUKEMIA & LYMPHOMA
- Patients' and physicians' roles in detecting recurrent Hodgkin lymphoma following complete remission
- (2012) A. Bestawros et al. ANNALS OF ONCOLOGY
- Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma
- (2012) R. Chen et al. BLOOD
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma
- (2011) Robert Chen et al. ANNALS OF HEMATOLOGY
- Positron emission tomography/computed tomography surveillance in patients with Hodgkin lymphoma in first remission has a low positive predictive value and high costs
- (2011) T. C. El-Galaly et al. HAEMATOLOGICA
- Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability
- (2010) B. Sarina et al. BLOOD
- Surveillance investigations after high-dose therapy with stem cell rescue for recurrent follicular lymphoma have no impact on management
- (2010) M. Gerlinger et al. HAEMATOLOGICA
- Unrelated Donor Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma
- (2009) Marcel P. Devetten et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Allogeneic Transplantation with Reduced-Intensity Conditioning for Hodgkin and non-Hodgkin Lymphoma: Importance of Histology for Outcome
- (2008) Philippe Armand et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Comparison of Outcomes of HLA-Matched Related, Unrelated, or HLA-Haploidentical Related Hematopoietic Cell Transplantation following Nonmyeloablative Conditioning for Relapsed or Refractory Hodgkin Lymphoma
- (2008) Lauri M. Burroughs et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience
- (2008) P. Anderlini et al. HAEMATOLOGICA
- Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome
- (2008) S. P. Robinson et al. HAEMATOLOGICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More